{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T03:10:16Z","timestamp":1778987416066,"version":"3.51.4"},"reference-count":43,"publisher":"American Chemical Society (ACS)","issue":"4","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol. Pharmaceutics"],"published-print":{"date-parts":[[2021,4,5]]},"DOI":"10.1021\/acs.molpharmaceut.1c00034","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T20:58:41Z","timestamp":1615323521000},"page":"1779-1791","source":"Crossref","is-referenced-by-count":11,"title":["Molecular Insights into Warfarin Sodium 2-Propanol Solvate Solid Form Changes and Disproportionation Using a Low Volume Two-Stage Dissolution Approach"],"prefix":"10.1021","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0678-5617","authenticated-orcid":true,"given":"Harsh S.","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Arnold and Marie Schwartz College of Pharmacy, Long Island University, 75 Dekalb Ave, Brooklyn, New York11201, United States"},{"name":"J-Star Research Inc., 6 Cedarbrook Drive, Cranbury, New Jersey08512, United States"},{"name":"Lachman Institute for Pharmaceutical Analysis, Long Island University, 75 Dekalb Ave, Brooklyn, New York11201, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushalendra","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Arnold and Marie Schwartz College of Pharmacy, Long Island University, 75 Dekalb Ave, Brooklyn, New York11201, United States"},{"name":"J-Star Research Inc., 6 Cedarbrook Drive, Cranbury, New Jersey08512, United States"},{"name":"Lachman Institute for Pharmaceutical Analysis, Long Island University, 75 Dekalb Ave, Brooklyn, New York11201, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rutesh H.","family":"Dave","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Arnold and Marie Schwartz College of Pharmacy, Long Island University, 75 Dekalb Ave, Brooklyn, New York11201, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9788-9894","authenticated-orcid":true,"given":"Kenneth R.","family":"Morris","sequence":"additional","affiliation":[{"name":"Lachman Institute for Pharmaceutical Analysis, Long Island University, 75 Dekalb Ave, Brooklyn, New York11201, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"316","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"ref1\/cit1","unstructured":"QuarterWatchTM (2016 Annual Report) Part II: Oral Anticoagulants\u2014The\nNation\u2019s Top Risk of Acute Injury from Drugs. https:\/\/www.ismp.org\/resources\/quarterwatchtm-2016-annual-report-part-ii-oral-anticoagulants-nations-top-risk-acute. (accessed 2020-06-30)"},{"key":"ref2\/cit2","unstructured":"United States Food and Drug\nAdministration.  Draft Guidance on\nWarfarin Sodium, 2012."},{"key":"ref3\/cit3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02806.x"},{"key":"ref4\/cit4","unstructured":"United States Pharmacopeia,  National Formulary. USP 41- NF36;\npp 6715\u20136717."},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-861503"},{"key":"ref6\/cit6","unstructured":"United States Food and Drug\nAdministration. Orange Book:\nApproved Drug Products with Therapeutic Equivalence Evaluations.  (accessed 2020-06-30)."},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1988.00380040046010"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.1107\/S1600536802005809"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20164"},{"key":"ref10\/cit10","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2003.10.007"},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1080\/10837450.2018.1425430"},{"key":"ref12\/cit12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2018.09.022"},{"key":"ref13\/cit13","doi-asserted-by":"publisher","DOI":"10.1021\/acs.cgd.0c01003"},{"key":"ref14\/cit14","unstructured":"United States Food and Drug\nAdministration. Drug Enforcement\nReport; 2020.  (accessed 2020-06-30)."},{"key":"ref15\/cit15","unstructured":"Lupkin, S. One-Third Of New Drugs Had Safety Problems After FDA Approval. (accessed 2020-10-07)"},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.11.014"},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.08.065"},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.2478\/acph-2014-0022"},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24524"},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2005.08.027"},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.07.051"},{"key":"ref22\/cit22","doi-asserted-by":"publisher","DOI":"10.3109\/03639045.2015.1058817"},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12198"},{"key":"ref24\/cit24","unstructured":"Hussain, A.NIPTE 2016 From Roadblocks to Roadmap- 2017, with a 2020 Vision. (accessed 2020-10-07)"},{"key":"ref25\/cit25","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-018-1264-0"},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.1208\/ps030103"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2006.06.004"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cplett.2018.03.053"},{"key":"ref29\/cit29","doi-asserted-by":"crossref","unstructured":"Hofmann, D. W.  Data mining in organic crystallography. Springer, 2009; pp. 89\u2013134.","DOI":"10.1007\/978-3-642-04759-6_4"},{"key":"ref30\/cit30","doi-asserted-by":"publisher","DOI":"10.1107\/S1600576719014092"},{"key":"ref31\/cit31","doi-asserted-by":"publisher","DOI":"10.4103\/0973-8398.150039"},{"key":"ref32\/cit32","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600730721"},{"key":"ref33\/cit33","volume-title":"The Merck index: an encyclopedia of chemicals, drugs, and biologicals","author":"O\u2019Neil M. J.","year":"2013"},{"key":"ref34\/cit34","doi-asserted-by":"publisher","DOI":"10.1088\/1674-1056\/22\/9\/098103"},{"key":"ref35\/cit35","doi-asserted-by":"publisher","DOI":"10.1002\/3527607889.ch8"},{"key":"ref36\/cit36","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.9b03886"},{"key":"ref37\/cit37","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24657"},{"key":"ref38\/cit38","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600510106"},{"key":"ref39\/cit39","first-page":"183","volume":"46","author":"Fallingborg J.","year":"1999","journal-title":"Danish med.l bull."},{"key":"ref40\/cit40","volume-title":"Coumarin anticoagulant hydroxycoumarin (81\u201381-2)","author":"MacBean C. E.","edition":"15"},{"key":"ref41\/cit41","volume-title":"Guidance for industry: dissolution testing of immediate release solid oral dosage forms","author":"United States Food and Drug Administration","year":"1997"},{"key":"ref42\/cit42","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00458-9"},{"key":"ref43\/cit43","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-019-1347-6"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.1c00034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T19:52:24Z","timestamp":1682625144000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.molpharmaceut.1c00034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,5]]}},"alternative-id":["10.1021\/acs.molpharmaceut.1c00034"],"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00034","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]}}}